Introduction
============

Coronary heart disease is responsible for one-third of deaths in patients aged more than 35 years in developed countries.[@b1-vhrm-15-057] In Europe, cardiovascular diseases cause approximately 4 million deaths annually, mainly owing to coronary heart disease. The disease generates costs of around €196,000 million per year, ie, 54% of all health care spending.[@b2-vhrm-15-057]

The European Society of Cardiology defines myocardial infarction (MI) as an alteration of markers of myocardial damage, mainly cardiac troponin (cTn), together with other clinical, electrocardiographic, and imaging data compatible with myocardial ischemia, although this definition is constantly changing.[@b3-vhrm-15-057]

Acute myocardial infarction (AMI) with no evidence of relevant stenosis of the coronary artery is known as MI with nonobstructive coronary arteries (MINOCA). Its prevalence ranges from 1% to 14% with a mean of 6%.[@b4-vhrm-15-057],[@b5-vhrm-15-057] The various causes of MINOCA lead to damage of the myocardium, and there are marked differences in diagnoses, prognoses, and treatments. Although the number of patients affected is considerable owing to the high prevalence of acute coronary syndrome (ACS), the causes of MINOCA have received little attention with the result that some patients may not receive appropriate treatment. Awareness of this disease among clinicians has started only to improve since the beginning of the current century, when the results of the first studies were published.

The causes of MINOCA are extremely varied. It can be classed as disease affecting the epicardial arteries and disease affecting the microcirculation. Other causes that do not directly involve coronary circulation include myocarditis, various prothrombotic diseases, and diseases preventing successful functioning of the heart.[@b6-vhrm-15-057] Since affected patients are not candidates for coronary revascularization, other therapeutic strategies are needed to improve health and quality of life.

Given the heterogeneous nature of the causes of MINOCA, prognostic studies are of limited value and may be influenced by the etiology and by the degree of damage associated with AMI. In any case, the disease is associated with greater mortality and risk of cardiovascular disease than in the general population, in both the short term and in the medium term.[@b4-vhrm-15-057],[@b5-vhrm-15-057]

Patients with MINOCA differ clinically from all other patients with AMI. They are more frequently younger, and the disease affects both sexes equally, unlike MI with coronary artery disease (MI-CAD). Patients with MINOCA tend to have fewer cardiovascular risk factors, and their serum markers of myocardial damage peak at lower levels.[@b4-vhrm-15-057],[@b5-vhrm-15-057],[@b7-vhrm-15-057]--[@b11-vhrm-15-057]

In Spain, the Spanish Society of Intensive Care Medicine and Coronary Unit (SEMICYUC) keeps a registry of acute coronary heart disease, the ARIAM (Analysis of Delay in AMI) registry, which has been kept running without interruption since 1994.[@b12-vhrm-15-057] The registry comprises clinical, diagnostic, and analytical data as well as prognostic tools, which form the basis of the present study.

Our aim was to develop a score that allows us to distinguish between patients with MINOCA and other patients with coronary disease on admission to hospital to reach a diagnosis and apply appropriate therapy. The secondary objective was to describe the characteristics of patients with MINOCA and their clinical course during admission and in the short term (30 days).

Patients and methods
====================

We performed a multicenter observational cohort study involving 69 hospitals in Spain and Andorra. Patients from the ARIAM-SEMICYUC registry were included prospectively and analyzed retrospectively. The registry includes all patients who were admitted to the intensive care unit (ICU) and coronary care unit (CCU) with a diagnosis of ACS.

The study included all patients aged ≥18 years and diagnosed with AMI within the previous 48 hours. The criteria for AMI and for the diagnosis of MINOCA were established according to those of the European Society of Cardiology in force.[@b13-vhrm-15-057] Patients that were not diagnosed with having AMI, minors with a personal history of coronary obstructive pathology, and those who did not undergo diagnostic coronary angiography during admission were excluded from the study.

We classified patients diagnosed with AMI into two groups: MINOCA, comprising patients with no previous diagnosis of coronary heart disease and no significant lesions (ie, no coronary artery stenosis ≥50%) on the angiogram at admission, and MI-CAD, comprising patients with previously known lesions of the coronary artery tree at admission or coronary obstructive disease on the coronary angiogram taken during admission and/or the need for coronary angioplasty.

The study period was from January 2010 to March 2015. Patients were followed for 30 days after discharge from the ICU or CCU.

The ARIAM-SEMICYUC registry comprises hundreds of variables adjusted to the recommendations of national guidelines and European guidelines (the Cardiology Audit and Registration Data Standards \[CARDS\] and European Data Standards for Clinical Cardiology Practice), the manuals of which can be accessed from the registry web page.[@b14-vhrm-15-057],[@b15-vhrm-15-057] The variables selected for the study were those that could be used to identify the onset of MINOCA, according to previously published studies.

Statistical analyses
--------------------

Categorical variables were expressed as absolute numbers and percentages. The chi-squared test was used to identify differences between the MINOCA and MI-CAD groups. Continuous variables are expressed as median (IQR). The Student's *t*-test was used to identify significant differences. Non-normal continuous variables were log transformed before the test was applied.

Actual survival was evaluated on censored data by the Kaplan--Meier (KM) function estimator. Cox proportional hazards regression models were used for multivariate analyses and to build a nomogram. The predictors analyzed initially included all variables that were statistically significant in bivariate analysis; nevertheless, to develop the final model, a backward step-down selection method was performed. The nomogram was created; meanwhile, the reduced model with only significant variables was included. Internal validation of nomogram was performed by discrimination and calibration analysis. For that aim, Harrell's concordance index (c-index) was used for quantifying the nomogram accuracy and, similarly, calibration plots were presented to further validate the nomogram. Calibration was assessed by grouping patients with respect to their nomogram-predicted probabilities and comparing the mean of the observed KM estimate of mortality at 30 days. The regression model was validated by analyzing the discriminative power of the model using the C-statistic (area under the receiver operating characteristic \[ROC\] curve) and the Hosmer--Lemeshow test.

The software used for the statistical analyses was STATA v.12^©^ (StataCorp LP, College Station, TX, USA).

Ethics
------

The study was approved by SEMICYUC for the use of the ARIAM-SEMICYUC registry. The rules for appropriate use of the registry were followed. The registry data that were released for the research were anonymized from aggregated public data. The ARIAM-SEMICYUC adheres to Spanish legislation on observational post-authorization studies for medicines for human use and the Spanish data protection law. Local clinical research ethics committee did not require patients to give their informed consent.

Results
=======

Characteristics of patients with MINOCA in the ARIAM-SEMICYUC registry
----------------------------------------------------------------------

During the study period, a total of 12,899 patients with AMI were included in the ARIAM-SEMICYUC project. Of these, 9,993 underwent coronary angiography; 9,241 were classed as MI-CAD and 752 as MINOCA. In this group, we excluded 130 patients who had a history of occlusive ischemic heart disease. The MINOCA group thus comprised 622 patients ([Figure 1](#f1-vhrm-15-057){ref-type="fig"}).

The characteristics of the study patients and their baseline characteristics are summarized in [Table 1](#t1-vhrm-15-057){ref-type="table"}. Patients from the MINOCA group were younger, had a higher rate of female gender, and had less cardiovascular risk factors than patients from the MI-CAD group. In addition, cardiovascular drugs were administered more frequently to patients from the MI-CAD group.

At baseline, all patients underwent a hemodynamic workup and electrocardiogram (ECG) and were classified according to the Killip class.[@b16-vhrm-15-057] Risk was assessed using the Global Registry of Acute Coronary Events (GRACE) and thrombolysis In myocardial infarction (TIMI) scores, as summarized in [Table 2](#t2-vhrm-15-057){ref-type="table"}.[@b17-vhrm-15-057],[@b18-vhrm-15-057] At the time of admission, the MINOCA group had less severe changes in the ECG and lower values in the Killip class, as well as in the TIMI and GRACE scores, than patients with MI-CAD.

[Table 3](#t3-vhrm-15-057){ref-type="table"} summarizes the occurrence of complications during ICU/CCU admission and at 30 days. Cardiovascular complications were more frequently present in the MI-CAD group during ICU/CCU stay, with special relevance of acute kidney failure (4% vs 1.3%, *P*\<0.001), cardiogenic shock (5.5% vs 2.2%, *P*\<0.001), and death (2.8% vs 1.1%, *P*=0.045). Compared with the MI-CAD group, fewer patients in the MINOCA group had higher levels (more than nine times the reference limit used by each center) of serum markers of myocardial damage ([Figure 2](#f2-vhrm-15-057){ref-type="fig"}), indicating a more extensive myocardial lesion.

At 30 days of follow-up, more complications related to cardiovascular problems were recorded in the MI-CAD group. The NYHA functional class was better in the MIN-OCA group.

Survival rate at 30 days was higher for the MI-CAD group, without statistical significance (*P*=0.632). The *P*-value of Wilcoxon test for the survival curves was 0.013 ([Figure 3](#f3-vhrm-15-057){ref-type="fig"}).

Creation of the MINOCA predictive score
---------------------------------------

A binomial logistic regression model was created using the stepwise method so that only significant variables were included in the final models. The dependent variable was the MINOCA/MI-CAD group; the independent variables were all those that were statistically significant in the bivariate analysis.

MINOCA was predicted by calculating the OR with its 95% CI and *P*-value. The results are presented in [Table 4](#t4-vhrm-15-057){ref-type="table"}, showing that the variables were used to construct the nomogram.

We found that the typical MINOCA patient was a nonsmoking woman aged \<50 years with cTn \<9 times the limit of the normal range and no personal history of arterial hypertension, diabetes mellitus, or AMI. The discriminative power was 0.756, which is close to unity and therefore confirms that the model can detect patients with MINOCA. Furthermore, the *P*-value for the Hosmer--Lemeshow test was \>0.05, thus indicating a good predictive adjustment of the regression model.

The MINOCA predictive score was created using the previous regression model, where the coefficients calculated in the final model were used to construct the predictive model in the form of a nomogram, that is, a graphical representation of the relative impact of each prognostic factor within the global model ([Figure 3](#f3-vhrm-15-057){ref-type="fig"}).

The predictive capacity of the final model was evaluated using calibration and the discriminative power that enabled the internal validation of the final model. The model was validated by means of the following tasks: A prognostic index (PI) was created using the following model: IP = α x + α x 1 × 1+\... + αkxk, that is, we kept the variable resulting from the model in our database. The sample was divided into risk groups by applying the cutoff points to the PI based on specific percentiles of patients with an event.The KM curves were constructed for the groups (observed survival). These were compared with those predicted for the model for the mean values of the PI in the groups.

[Figure 4](#f4-vhrm-15-057){ref-type="fig"} shows the probability that a patient with AMI has MINOCA at admission. The score value was obtained by summing the scores for the variables that comprised the nomogram. The values ranged from 0 to 48. The maximum value corresponded to a 40% probability of MINOCA.

Discussion
==========

The ARIAM project has become one of the most important registries of ACS in the world with data from more than 160,000 patients throughout Spain and Andorra.[@b19-vhrm-15-057]--[@b22-vhrm-15-057]

The data obtained show that patients with MINOCA account for 6% of all cases of AMI diagnosed in Spain. The main characteristics of these patients are as follows: younger age than patients with obstructive coronary disease with no differences in distribution by gender; fewer risk factors for cardiovascular disease or known cardiovascular conditions before admission; less severe disease during admission and, therefore, a lower rate of complications, including death.

Although these characteristics had already been reported elsewhere, they had never been reviewed in Spain. As our findings are consistent with previously published data, they can be generalized to the whole of Spain.[@b4-vhrm-15-057],[@b5-vhrm-15-057],[@b9-vhrm-15-057]--[@b11-vhrm-15-057],[@b23-vhrm-15-057]--[@b25-vhrm-15-057]

As shown in [Table 5](#t5-vhrm-15-057){ref-type="table"}, the rate of MINOCA was about 6% in most reported series of patients in agreement with our results. The high incidence of coronary artery disease throughout the world means that the number of patients with MINOCA is also high. If we take the available data from the hospital morbidity survey of the Spanish National Statistics Institute (ie, 54,090 discharges with a diagnosis of AMI), and given a prevalence of around 6% of patients with AMI, then approximately 3,400 patients had MINOCA in Spain in 2014.[@b26-vhrm-15-057]

Although no registry data are available, medication is usually withdrawn from MINOCA patients before the end of the workup, thus underestimating the importance of the process without reaching a definitive diagnosis, as these patients are not thought to be at risk of death. This entails consequences for the patients since their prognosis is not that of the general population.[@b27-vhrm-15-057] Unlike this assumption for patients with MINOCA, morbidity and mortality are increased in the short, medium, and long terms, with the onset of new episodes of acute ischemic heart disease and death. In the ACUITY study, the adjusted risk of death at 1 year was 5.2%, which the researchers attributed to the poorer prognosis of these patients and the possible lack of assessment and treatment of the origin of the increase in AMI after coronary angiography.[@b28-vhrm-15-057] Therefore, some of the patients did not receive appropriate treatment with the possibility that the disease could progress or the event could recur.

Patients with MINOCA presented an event that led to myocardial ischemia with necrosis of myocardium. The present tool enables clinicians to suspect the presence of nonobstructive disease and act earlier to schedule new diagnostic tests and to prescribe appropriate therapy.

In 2000, Roe et al[@b24-vhrm-15-057] published the results of a study where they attempted to differentiate between patients with ACS without ST segment elevation who had obstructive disease and those who did not. The authors aimed to be able to distinguish between patients on administering treatment with anti-IIb/IIIa antiplatelet therapy. Their results show that patients with non-obstructive disease share characteristics with the MINOCA patients in our study. The authors designed a predictive score based on the patients' baseline characteristics with a C-statistic value of 0.827, indicating that the model can reliably predict the presence of coronary artery disease without significant obstruction. Furthermore, when the predictive model was applied to the patients in the GUSTO-IIb trial, the C-statistic was 0.796, indicating excellent discrimination of the model when applied to a different population.[@b29-vhrm-15-057] In contrast with this algorithm, our score is aimed at patients with a diagnosis of AMI, and it is also easier to perform, since it is done with values that are easily obtained at the patient's admision.

MINOCA is currently diagnosed based on coronary angiography to rule out coronary obstruction. In the case of patients who fulfill the diagnostic criteria for MINOCA, every attempt should be made to determine the etiology to manage the condition appropriately, since the origin may not even be cardiac, thus necessitating specific assessment and therapy.[@b29-vhrm-15-057] In this way, the application of a score elaborated with immediate clinical data could allow clinicians to choose patients for the accomplishment of minimally invasive diagnostic tests, which allow them to exclude coronary disease.[@b30-vhrm-15-057] Recent reports have demonstrated that computed tomography (CT) coronary angiography can target planned interventions in patients with angina, including coronary angiography, improving outcome.[@b56-vhrm-15-057],[@b57-vhrm-15-057] It is needed to carry out a study aimed to show a reduction in coronary angiography of patients with suspected MINOCA through less invasive procedure such as CT coronary angiography or other imaging tests.

Limitations of the study
------------------------

The main limitation of our study is the lack of alternative diagnosis for MINOCA patients. Due to the short-term follow-up of the ARIAM registry, additional studies and definitive diagnosis are not known for these patients.

Another limitation of our score is the relatively low predictive value (40% probability of MINOCA with the highest score), although other widely used scores show similar values. The TIMI risk score for unstable angina and non-ST segment elevation showed a probability of 40.9% for all-cause mortality, MI, and severe recurrent ischemia prompting urgent revascularization through 14 days for the maximum score value.[@b58-vhrm-15-057] The risk prediction tool from the GRACE study showed C-statistics of 0.81 for predicting death and 0.73 for death or MI from admission to 6 months after discharge, which is similar to our results.[@b59-vhrm-15-057]

Conclusion
==========

In our registry, patients with MINOCA present characteristics which differentiate them early from those with MI-CAD. The diagnosis of MINOCA does not suppose the exclusion of an unfavorable outcome or future complications.

The score we present can accurately predict the diagnosis of MINOCA, encouraging clinicians to perform alternative tests for the correct diagnosis of these patients and allowing a correct treatment. This score is determined easily and quickly, not requiring tests in addition to those performed in the current ACS protocols. Further trials to establish definitive diagnosis for these patients are needed.
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![Flowchart of the selection process.\
**Abbreviations:** AMI, acute myocardial infarction; ARIAM, Analysis of Delay in AMI; IHD, ischemic heart disease; MI-CAD, myocardial infarction with coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries; PCI, percutaneous coronary intervention; SEMICYUC, Spanish Society of Intensive Care Medicine and Coronary Unit.](vhrm-15-057Fig1){#f1-vhrm-15-057}

![Plasma levels of markers of myocardial damage.\
**Notes:** The proportion of patients with different peaks of the level of markers of myocardial injury is shown. n denotes the limit of the laboratory normal range.\
**Abbreviations:** MI-CAD, myocardial infarction with coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries.](vhrm-15-057Fig2){#f2-vhrm-15-057}

![Mortality at 30 days of follow-up.\
**Note:** Patients with follow-up completed at 30 days are included in the figure.\
**Abbreviations:** MI-CAD, myocardial infarction with coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries.](vhrm-15-057Fig3){#f3-vhrm-15-057}

![Nomogram for predicting MINOCA.\
**Note:** Impact of each prognostic factor within the global model. n denotes the limit of the laboratory normal range.\
**Abbreviations:** AMI, acute myocardial infarction; MINOCA, myocardial infarction with nonobstructive coronary arteries; Prob, probability.](vhrm-15-057Fig4){#f4-vhrm-15-057}

###### 

Demographic and baseline variables

  Variables                                  MI-CAD (N=9,241) N (%)   MINOCA (N=622) N (%)   *P*-value
  ------------------------------------------ ------------------------ ---------------------- -----------
  Gender, female                             2,019 (21.9)             305 (49.0)             \<0.001
  Age (years), median (IQR)                  65 (55--75)              63 (50--74)            \<0.001
  BMI, median (IQR)                          27.3 (25.0--29.9)        27.0 (24.5--29.4)      0.32
  Ex-smoker                                  2,207 (23.9)             87 (14)                \<0.001
  Current smoker                             3,360 (36.4)             169 (27.1)             \<0.001
  Nonsmoker                                  2,839 (30.7)             294 (47.3)             \<0.001
  Hypertension                               5,443 (58.9)             326 (52.4)             0.001
  Known CAD                                  1,396 (15.1)             0 (0.0)                \<0.001
  Family history of ischemic heart disease   1,088 (11.7)             71 (11.4)              0.594
  Dyslipidemia                               4,722 (51.1)             275 (44.2)             \<0.001
  Diabetes mellitus                          2,590 (28.0)             116 (18.7)             \<0.001
  Consumption of cocaine                     96 (1.0)                 11 (1.8)               0.069
  Previous angina                            1,695 (18.3)             89 (14.3)              0.012
  Previous AMI                               1,554 (16.8)             29 (4.7)               \<0.001
  Stroke                                     514 (5.5)                25 (4.0)               0.1
  Peripheral artery disease                  593 (6.4)                14 (2.2)               \<0.001
  Heart failure                              280 (3.0)                19 (3.1)               0.965
  COPD                                       701 (7.6)                39 (6.3)               0.227
  Chronic kidney disease                     445 (4.8)                19 (3.1)               0.046
  **Treatment before admission**                                                             
  Acetylsalicylic acid                       2,396 (25.9)             88 (14.2)              \<0.001
  Other antiplatelet agents                                                                  
   None                                      8,318 (90.0)             600 (96.5)             \<0.001
   Clopidogrel                               784 (8.5)                21 (3.4)               \<0.001
   Prasugrel                                 35 (0.4)                 0 (0.0)                0.168
   Ticagrelor                                21 (0.2)                 0 (0.0)                0.64
   Others                                    71 (0.8)                 1 (0.1)                0.089
  Nitrates                                   656 (7.1)                25 (4.0)               0.003
  Beta-blockers                              1,743 (18.9)             91 (14.6)              0.008
  Calcium channel antagonists                1,168 (12.7)             59 (9.5)               0.02
  ACEI/ARA-II                                3,318 (35.9)             200 (32.1)             0.054
  Statins/other lipid-lowering drugs         3,294 (35.6)             176 (28.3)             \<0.001
  Oral anticoagulants                        379 (4.1)                38 (6.1)               0.017

**Abbreviations:** ACEI, angiotensin-converting enzyme inhibitors; AMI, acute myocardial infarction; ARA-II, angiotensin receptor antagonists-II; BMI, body mass index; CAD, coronary artery disease; MI-CAD, myocardial infarction with CAD; MINOCA, myocardial infarction with nonobstructive coronary arteries.

###### 

Assessment on admission

  Variables                                  MI-CAD (N=9,241) N (%)   MINOCA (N=622) N (%)   *P*-value
  ------------------------------------------ ------------------------ ---------------------- -----------
  **ECG at admission**                                                                       
   ECG normal                                462 (5.0)                67 (10.8)              \<0.001
   New LBBB                                  73 (0.8)                 10 (1.6)               0.018
   ST segment depression \<0.5 mm            408 (4.4)                37 (6.0)               0.03
   ST depression ≥0.5 mm                     1,057 (11.4)             72 (11.6)              0.513
   ST elevation \<2 mm                       924 (10.0)               76 (12.2)              0.019
   ST elevation ≥2 mm                        4,194 (45.4)             119 (19.1)             \<0.001
   Transient ST elevation (\<20 minutes)     339 (3.7)                37 (6.0)               0.001
   T wave inversion                          807 (8.7)                112 (18.0)             \<0.001
   LMCA/multivessel pattern                  150 (1.6)                2 (0.3)                0.009
   Others/unknown                            827 (9.0)                90 (14.4)              \<0.001
  **Hemodynamic values**                                                                     
   Killip class I                            7,280 (78.8)             516 (83.0)             0.014
   Killip class II                           1,218 (13.2)             70 (11.2)              0.166
   Killip class III                          479 (5.2)                29 (4.7)               0.567
   Killip class IV                           259 (2.8)                7 (1.1)                0.012
  Systolic pressure (mmHg), median (IQR)     135 (118--153)           134 (120--150)         0.934
  Diastolic pressure (mmHg), median (IQR)    75 (65.5--88)            75 (65--87)            0.141
  Heart rate (bpm), median (IQR)             75 (65--89)              78 (67--90)            \<0.001
  **Laboratory values**                                                                      
  Creatinine (mg/dL), median (IQR)           0.93 (0.8--1.1)          0.90 (0.7--1.1)        \<0.001
  Platelet count (×10^3^/mL), median (IQR)   189 (155--228)           199 (169--237)         0.005
  Total cholesterol (mg/dL), median (IQR)    168 (139--199)           170.5 (140.5--199.5)   0.611
  HDL cholesterol (mg/dL), median (IQR)      39 (33--47)              45 (36--54)            \<0.001
  Triglycerides (mg/dL), median (IQR)        119 (89--163)            111 (82.5--154)        0.012
  Hematocrit (%), median (IQR)               42 (38.1--45)            41.2 (37.8--43.4)      0.024
  Hemoglobin (g/L), median (IQR)             14 (12.9--15.2)          13.9 (12.7--14.8)      0.086
  **Evaluation of risk**                                                                     
  TIMI score, median (IQR)                   3 (2--4)                 2 (1--3)               \<0.001
  GRACE score, median (IQR)                  142 (120--168)           126.5 (100.5--153)     \<0.001

**Abbreviations:** ECG, electrocardiogram; GRACE, Global Registry of Acute Coronary Events; HDL, high-density lipoprotein; LBBB, left bundle branch block; LMCA, left mean coronary artery; MI-CAD, myocardial infarction with coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries; TIMI, thrombolysis in myocardial infarction.

###### 

Outcomes

  Complications                                                      MI-CAD (N=9,241) N (%)   MINOCA (N=622) N (%)   *P*-value
  ------------------------------------------------------------------ ------------------------ ---------------------- -----------
  **During ICU/CCU admission**                                                                                       
  Hemorrhage requiring transfusion or with hemodynamic instability   55 (0.6)                 1 (0.2)                0.261
  Stroke                                                                                                             
   Hemorrhagic                                                       9 (0.1)                  0 (0.0)                1
   Ischemic                                                          38 (0.4)                 0 (0.0)                0.169
  Acute kidney failure                                               367 (4.0)                8 (1.3)                0.001
  Reinfarction                                                       138 (1.5)                1 (0.2)                0.003
  Post-AMI angina                                                    212 (2.3)                4 (0.6)                0.005
  Cardiac tamponade                                                  47 (0.5)                 1 (0.2)                0.368
  Pulmonary embolism                                                 4 (0.1)                  3 (0.5)                0.007
  Right heart failure                                                72 (0.8)                 1 (0.2)                0.131
  Cardiogenic shock                                                  509 (5.5)                14 (2.2)               \<0.001
  Death                                                              263 (2.8)                7 (1.1)                0.045
  **At 30 days**                                                                                                     
  NYHA functional class                                                                                              
   NYHA I                                                            3,502 (37.9)             276 (44.4)             0.044
   NYHA II                                                           1,435 (15.5)             81 (13.0)              0.008
   NYHA III                                                          367 (4.0)                32 (5.1)               0.323
   NYHA IV                                                           95 (1.0)                 6 (1.0)                0.724
  Need for coronary angiography                                      247 (2.7)                5 (0.8)                0.001
  Need for PCI                                                       136 (1.5)                0 (0.0)                \<0.001
  Readmission                                                        468 (5.1)                27 (4.4)               0.256
  New AMI                                                            64 (0.7)                 0 (0.0)                0.021
  CPR                                                                11 (0.1)                 0 (0.0)                1
  Death                                                              69 (0.8)                 3 (0.5)                0.632

**Abbreviations:** AMI, acute myocardial infarction; CCU, coronary care unit; CPR, cardiopulmonary resuscitation; ICU, intensive care unit; MI-CAD, myocardial infarction with coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.

###### 

Statistically significant variables

  Variables                      OR      *P*-value   95% CI   
  ------------------------------ ------- ----------- -------- ------
  Gender, female                 3.52    \<0.001     2.58     4.81
  Age \>50 years                 0.37    \<0.001     0.25     0.53
  Troponin \>9-fold              0.53    \<0.001     0.38     0.74
  Smoker                         0.62    \<0.001     0.51     0.75
  Hypertension                   0.63    0.004       0.46     0.86
  Diabetes mellitus              0.59    0.012       0.4      0.89
  Previous infarction            0.4     0.009       0.2      0.79
  *P*-value (Hosmer--Lemeshow)   0.157                        
  C-statistic                    0.756                        

###### 

Prevalence of MINOCA in most relevant studies

  Authors of the studies / year of publication   Proportion (95% CI)
  ---------------------------------------------- -------------------------
  Larsen et al[@b32-vhrm-15-057] / 2013          0.04 (0.03 -- 0.04)
  Collste et al[@b31-vhrm-15-057] / 2013         0.06 (0.06 -- 0.07)
  Sun et al[@b33-vhrm-15-057] / 2012             0.02 (0.00 -- 0.03)
  Rhew et al[@b34-vhrm-15-057] / 2012            0.08 (0.07 -- 0.10)
  Hamdan et al[@b35-vhrm-15-057] / 2012          0.09 (0.04 -- 0.14)
  Aldrovandi et al[@b36-vhrm-15-057] / 2012      0.04 (0.03 -- 0.04)
  Agewall et al[@b9-vhrm-15-057] / 2012          0.07 (0.03 -- 0.11)
  Tritto et al[@b37-vhrm-15-057] / 2011          0.05 (0.04 -- 0.06)
  Leurent et al[@b38-vhrm-15-057] / 2011         0.13 (0.11 -- 0.16)
  Kang et al[@b39-vhrm-15-057] / 2011            0.04 (0.04 -- 0.12)
  Uchida et al[@b40-vhrm-15-057] / 2010          0.08 (0.04 -- 0.12)
  Frycz-Kurek et al[@b41-vhrm-15-057] / 2010     0.03 (0.03 -- 0.03)
  Gehrie et al[@b42-vhrm-15-057] / 2009          0.10 (0.07 -- 0.13)
  Baccouche et al[@b43-vhrm-15-057] / 2009       0.14 (0.12 -- 0.16)
  Ong et al[@b44-vhrm-15-057] / 2008             0.10 (0.07 -- 0.13)
  Ahmar et al[@b45-vhrm-15-057] / 2008           0.06 (0.05 -- 0.07)
  Larson et al[@b46-vhrm-15-057] / 2007          0.04 (0.03 -- 0.05)
  Widimsky et al[@b47-vhrm-15-057] / 2006        0.03 (0.02 -- 0.04)
  Strunk et al[@b48-vhrm-15-057] / 2006          0.08 (0.05 -- 0.10)
  Patel et al[@b11-vhrm-15-057] / 2006           0.09 (0.08 -- 0.09)
  Larsen et al[@b49-vhrm-15-057] / 2005          0.07 (0.07 -- 0.08)
  Germing et al[@b50-vhrm-15-057] / 2005         0.06 (0.04 -- 0.08)
  Hung et al[@b51-vhrm-15-057] / 2003            0.10 (0.06 -- 0.14)
  Gehani et al[@b52-vhrm-15-057] / 2001          0.05 (0.04 -- 0.06)
  Hochman et al[@b53-vhrm-15-057] / 1999         0.07 (0.06 -- 0.07)
  Zimmerman et al[@b54-vhrm-15-057] / 1995       0.04 (0.04 -- 0.05)
  Sharifi et al[@b55-vhrm-15-057] / 1995         0.01 (0.00 -- 0.02
  **Overall**                                    **0.06 (0.05 -- 0.07)**
  **Ballesteros et al**                          **0.06 (0.06 -- 0.07)**

**Notes:** Prevalence of MINOCA in various studies (overall 6%, in red text; systematic review from Pasupathy et al[@b4-vhrm-15-057]) compared with the present study (blue text), showing 6.3% of patients with MINOCA diagnosis.

**Abbreviations:** MINOCA, myocardial infarction with nonobstructive coronary arteries.
